Hepatitis C News and Research

Latest Hepatitis C News and Research

Medco enters definitive merger agreement with Express Scripts

Express Scripts, Inc. and Medco Health Solutions, Inc. today announced that they have entered into a definitive merger agreement.

21 Jul 2011

Cell biologists identify infection mechanism of adenoviruses

Mucosal epithelia do not have any receptors on the outer membrane for the absorption of viruses like hepatitis C, herpes, the adenovirus or polio, and are thus well-protected against pathogenic germs. However, certain viruses, such as the human immunodeficiency virus HIV, still manage to enter the body via the mucous membrane.

21 Jul 2011

WHO warning increases opportunity for Biomagnetics urine based TB assay

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced that the World Health Organization ("WHO") on Sunday July 17, 2011 warned that the widely used blood tests to detect tuberculosis ("TB") are unreliable and "dangerous" to patients because they produce too many false negatives and positives.

21 Jul 2011

IAS, UIPHP to launch VKC for injecting drug users living with HIV

As a part of its new initiative, Expanding Access to Opioid Substitution Therapy (OST) for People Who Inject Drugs in Eastern Europe and Central Asia (EECA), the International AIDS Society (IAS) will launch a Virtual Knowledge Centre (VKC) in partnership with the Ukrainian Institute on Public Health Policy.

21 Jul 2011

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Merck, known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin.

21 Jul 2011

Final SVR results from Pharmasset's PSI-7977 phase 2b study in HCV

Pharmasset, Inc. announced today the final sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 dosed once daily in combination with peginterferon alfa 2a and ribavirin in subjects with hepatitis C virus (HCV) genotype 2 or 3 who have not been treated previously.

20 Jul 2011

Scientists define structure of astrovirus that causes juvenile diarrhea

Rice University scientists have defined the structure -- down to the atomic level -- of a virus that causes juvenile diarrhea. The research may help direct efforts to develop medications that block the virus before it becomes infectious.

19 Jul 2011

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

SEEK, a privately owned biopharmaceutical company specializing in immunology, announces today that it has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single vaccine injection.

18 Jul 2011

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.

15 Jul 2011

Opinions about the CIA's ruse vaccination campaign in Pakistan

Health experts and writers continue to react to the CIA's use of a vaccine campaign to hunt Osama bin Laden.

15 Jul 2011

Global health community reacts to CIA's faux vaccine operation in Pakistan

After the Guardian broke the story that the CIA organized a fake vaccination program in Pakistan in an effort to confirm the location of Osama bin Laden and obtain DNA from his family members, several writers and health experts reacted to the situation, noting the possible implications for health.

14 Jul 2011

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

EC approves YERVOY for treatment of previously-treated advanced melanoma

Bristol-Myers Squibb today announced that the European Commission has approved YERVOY for the treatment of adult patients with previously-treated advanced melanoma.

14 Jul 2011

PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate

PharmAthene, Inc. announced today that it has achieved an important program milestone in its recombinant protective antigen (rPA) anthrax vaccine program and demonstrated 36 month stability of its rPA drug product candidate previously produced at Avecia Biologics Laboratories in the United Kingdom. The stability data were prepared utilizing a variety of analytical methods and a well characterized mouse challenge potency assay.

14 Jul 2011

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).

14 Jul 2011

Adamis receives European patent for novel cell-based cancer vaccine technology

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe.

14 Jul 2011

AHF applauds Gilead for licensing AIDS drugs to Medicines Patent Pool

AIDS Healthcare Foundation (AHF) today lauded Gilead Sciences for being the first major AIDS drug company to share some drug patents with a new international Medicines Patent Pool, a move that will help ensure access to newer AIDS treatments in developing countries.

13 Jul 2011

Gilead becomes first company to license drugs to Medicines Patent Pool

"In the first agreement between a pharmaceutical company and the new international Medicines Patent Pool, Gilead Sciences announced Tuesday that it would license four of its AIDS and hepatitis B drugs to the pool," the New York Times reports.

13 Jul 2011

BRICS health ministers agree to improve access to low-cost medicines

Health ministers from Brazil, Russia, India, China, and South Africa in Beijing "on Monday vowed to improve access to low-cost and high-quality medicine - and called on developed nations to shoulder responsibility in helping the poor," Agence France-Presse reports.

13 Jul 2011

Sequana Medical's ALFApump System for liver cirrhosis receives CE Mark approval

Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump System.

13 Jul 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Medco enters definitive merger agreement with Express Scripts

Cell biologists identify infection mechanism of adenoviruses

WHO warning increases opportunity for Biomagnetics urine based TB assay

IAS, UIPHP to launch VKC for injecting drug users living with HIV

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Final SVR results from Pharmasset's PSI-7977 phase 2b study in HCV

Scientists define structure of astrovirus that causes juvenile diarrhea

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Opinions about the CIA's ruse vaccination campaign in Pakistan

Global health community reacts to CIA's faux vaccine operation in Pakistan

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

EC approves YERVOY for treatment of previously-treated advanced melanoma

PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Adamis receives European patent for novel cell-based cancer vaccine technology

AHF applauds Gilead for licensing AIDS drugs to Medicines Patent Pool

Gilead becomes first company to license drugs to Medicines Patent Pool

BRICS health ministers agree to improve access to low-cost medicines

Sequana Medical's ALFApump System for liver cirrhosis receives CE Mark approval

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in